Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  American Journal of Cardiology

• Publication date

  1993-03-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0002-9149(93)90082-NPMID 8096671
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The pharmacology of carvedilol

  2005cited by this paper
• Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes

  2004cited by this paper
• Congestive Heart Failure

  1994cited by this paper
• Effect of long-term carvedilol therapy on renal function in essential hypertension.

  1992cited by this paper
• The paradox of beta-adrenergic blockade for the management of congestive heart failure.

  1992cited by this paper
• Spare Receptors for β‐Adrenoceptor-Mediated Positive Inotropic Effects of Catecholamines in the Human Heart

  1992cited by this paper
• Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte

  1992cited by this paper
• Positive Inotropic Effects Due to Partial Agonistic Activity of the β‐Adrenoceptor Antagonist Celiprolol Following Amplification of cAMP Formation in Failing Human Myocardium

  1992cited by this paper
• Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms.

  1992cited by this paper
• The paradox of β-adrenergic blockade for the management of congestive heart failure

  1992cited by this paper
• Receptor pharmacology of carvedilol in the human heart.

  1992cited by this paper
• Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias.

  1992cited by this paper
• Dobutamine is a partial agonist with an intrinsic activity of 0.5 in human myocardium

  1991cited by this paper
• Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy

  1991cited by this paper
• Comparison of sympathetic innervation of failing and nonfailing human hearts by quantitative evaluation of catecholamine fluorescence

  1991cited by this paper
• Xamoterol has agonist activity in end-stage failing human heart

  1991cited by this paper
• Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy.

  1991cited by this paper
• Beta receptor antagonists in the treatment of heart failure

  1991cited by this paper
• Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy.

  1991cited by this paper
• The Effects of Intravenous Carvedilol, A New Multiple Action Vasodilatory β‐Blocker, in Congestive Heart Failure

  1991cited by this paper
• Acute haemodynamic profile of celiprolol in patients with coronary heart disease and hypertension: a double-blind comparison with metoprolol.

  1991cited by this paper
• Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy.

  1991cited by this paper
• Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo.

  1990cited by this paper
• Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol.

  1990cited by this paper
• Dilevalol: An Overview of Its Clinical Pharmacology and Therapeutic Use in Hypertension

  1990cited by this paper
• Xamoterol in severe heart failure.

  1990cited by this paper
• Mechanism of Action of Bucindolol in Human Ventricular Myocardium

  1990cited by this paper
• Usefulness of bucindolol in congestive heart failure.

  1990cited by this paper
• Hemodynamic Effects of Nebivolol at Rest and on Exertion in Patients with Heart Failure

  1990cited by this paper
• Pharmacology of antihypertensive agents with multiple actions.

  1990cited by this paper
• Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium.

  1990cited by this paper
• Effect of intravenous metoprolol on left ventricular performance in Q-wave acute myocardial infarction.

  1989cited by this paper
• Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.

  1989cited by this paper
• Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.

  1989cited by this paper
• Effects of (+)- and (±)-sotalol on repolarizing outward currents and pacemaker current in sheep cardiac Purkinje fibres

  1989cited by this paper
• Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.

  1989cited by this paper
• Localization of a "postreceptor" defect in human dilated cardiomyopathy.

  1989cited by this paper
• Celiprolol--overview of 6 years of clinical trials experience.

  1988cited by this paper
• Pharmacological and therapeutic properties of an ideal beta-blocker.

  1988cited by this paper
• Molecular mechanism of β‐adrenergic receptor blockers with intrinsic sympathomimetic activity

  1988cited by this paper
• Hemodynamic Effects of Labetalol in Patients with Combined Hypertension and Left Ventricular Failure

  1988cited by this paper
• Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist.

  1988cited by this paper
• Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart.

  1988cited by this paper
• 6-Hydroxydopamine mediated cardiotoxicity in rabbits.

  1988cited by this paper
• Hemodynamic effects of beta-blocking compounds possessing vasodilating activity: a review of labetalol, prizidilol, and dilevalol.

  1988cited by this paper
• Cardiopulmonary baroreflexes fail to modulate sympathetic responses during isometric exercise in humans: direct evidence from microneurographic studies.

  1988cited by this paper
• Increase in myocardial Gi-proteins in heart failure.

  1988cited by this paper
• Alpha-1 adrenergic receptors in the nonfailing and failing human heart.

  1988cited by this paper
• Neurohormonal interactions and adaptations in congestive heart failure.

  1988cited by this paper
• Celiprolol--overview of 6 years of clinical trials experience.

  1988cited by this paper
• Pharmacological Profile of Carvedilol, a Compound with &bgr;‐Blocking and Vasodilating Properties*

  1987cited by this paper
• Long-term experience with sotalol in the treatment of complex ventricular arrhythmias.

  1987cited by this paper
• Effects of adrenergic receptor antagonists on cardiac morphological and functional alterations in rats harboring pheochromocytoma.

  1987cited by this paper
• Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma.

  1987cited by this paper
• Is the ISA of pindolol beta 2-adrenoceptor selective?

  1987cited by this paper
• Effect of Carvedilol on Ambulatory Blood Pressure, Renal Hemodynamics, and Cardiac Function in Essential Hypertension

  1987cited by this paper
• Acute Hemodynamic and Neurohumoral Effects of Pindolol: A β‐Adrenoceptor Antagonist with High Intrinsic Sympathomimetic Activity in Patients with Dilated Cardiomyopathy

  1987cited by this paper
• Reduction of stress/catecholamine-induced cardiac necrosis by beta 1-selective blockade.

  1987cited by this paper
• Acute Hemodynamic Effects of the Vasodilating and &bgr;‐Blocking Agent Carvedilol in Comparison to Propranolol

  1987cited by this paper
• Regional distribution of beta-adrenoceptors in the human heart: coexistence of functional beta 1- and beta 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy.

  1986cited by this paper
• Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity.

  1986cited by this paper
• Hemodynamic-inotropic response to beta-blocker with intrinsic sympathomimetic activity in patients with congestive cardiomyopathy.

  1986cited by this paper
• Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

  1986cited by this paper
• Mode of action of (‐)‐pindolol on feline and human myocardium

  1986cited by this paper
• Acute hemodynamic effects of bisoprolol, a new beta 1 selective adrenoreceptor blocking agent, in patients with coronary artery disease.

  1986cited by this paper
• A comparison of the effects of beta-blockers with and without intrinsic sympathomimetic activity on hemodynamics and left ventricular function at rest and during exercise in patients with coronary artery disease.

  1986cited by this paper
• A Comparison of the Effects of β‐Blockers With and Without Intrinsic Sympathomimetic Activity on Hemodynamics and Left Ventricular Function at Rest and During Exercise in Patients with Coronary Artery Disease

  1986cited by this paper
• Regional Distribution of β‐Adrenoceptors in the Human Heart: Coexistence of Functional β1 and β2-Adrenoceptors in Both Atria and Ventricles in Severe Congestive Cardiomyopathy

  1986cited by this paper
• Acute Hemodynamic Effects of Bisoprolol, a New β1, Selective Adrenoreceptor Blocking Agent, in Patients with Coronary Artery Disease

  1986cited by this paper
• Cardiopulmonary exercise testing for evaluation of chronic cardiac failure.

  1985cited by this paper
• The sympathomimetic activity of (±)-pindolol at β1- and β2-adrenoceptor sites

  1985cited by this paper
• The sympathomimetic activity of (+/-)-pindolol at beta 1- and beta 2-adrenoceptor sites.

  1985cited by this paper
• Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure and volume overload.

  1985cited by this paper
• Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers.

  1985cited by this paper
• Beta-adrenergic function in heart muscle disease and heart failure.

  1985cited by this paper
• Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.

  1985cited by this paper
• Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure.

  1984cited by this paper
• Effects of celiprolol (REV 5320), a new cardioselective beta-adrenoceptor antagonist, on in vitro adenylate cyclase, alpha- and beta-adrenergic receptor binding and lipolysis.

  1984cited by this paper
• Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.

  1984cited by this paper
• Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.

  1984cited by this paper
• Pharmacology of bucindolol in isolated canine vascular smooth muscle.

  1984cited by this paper
• Labetalol: Current Research and Therapeutic Status

  1983cited by this paper
• Beta-blockers in dilated cardiomyopathies: they work.

  1983cited by this paper
• Reduced aortocoronary sinus extraction of epinephrine in patients with left ventricular failure secondary to long-term pressure or volume overload.

  1983cited by this paper
• Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure.

  1982cited by this paper
• Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful?

  1982cited by this paper
• Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

  1982cited by this paper
• Haemodynamic effects of beta-blockade in ischaemic heart failure.

  1981cited by this paper
• Beneficial effects of long-term beta-blockade in congestive cardiomyopathy.

  1980cited by this paper
• A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data.

  1980cited by this paper
• Uptake of catecholamines by human cardiac muscle in vitro.

  1979cited by this paper
• Clinical pharmacology of labetalol.

  1979cited by this paper
• Plasma norepinephrine in congestive heart failure.

  1978cited by this paper
• Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin.

  1977cited by this paper
• Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.

  1975cited by this paper
• Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists.

  1973cited by this paper
• Catecholamines and cardiomyopathy: The pathogenesis and potential importance of myofibrillar degeneration

  1970cited by this paper
• Blockade of cardiac effects of isoproterenol by the stereoisomers of sotalol.

  1969cited by this paper
• A comparison of the antiarrhythmic actions of two new synthetic compounds, iproveratril and MJ 1999, with quinidine and pronethalol.

  1967cited by this paper
• Unwanted effects of propranolol.

  1966cited by this paper

• Does atenolol use during pregnancy cause small for gestational age neonates? A meta-analysis

  2024cites this paper
• Involvement of protein kinases associated signal transduction mechanisms in cardiac diseases

  2023cites this paper
• Effect of Beta-Blocker Cardioselectivity on Vascular Refilling in Hemodialysis Patients

  2021cites this paper
• Long‐term impact of β‐blocker in elderly patients without myocardial infarction after percutaneous coronary intervention

  2021influential citation
• Pharmacology of Cardiovascular Drugs

  2019cites this paper
• Do beta adrenoceptor blocking agents provide the same degree of clinically convincing morbidity and mortality benefits in patients with chronic heart failure? A literature review

  2019cites this paper
• Cardiac autonomic activity in depression and anxiety: Heartfelt afflictions of the mind

  2019cites this paper
• Beta‐blocker subtypes and risk of low birth weight in newborns

  2018cites this paper
• Temporal stability and drivers of change in cardiac autonomic nervous system activity.

  2017cites this paper
• Phosphodiesterase 2 Protects Against Catecholamine-Induced Arrhythmia and Preserves Contractile Function After Myocardial Infarction

  2017cites this paper
• CH Bond Activation as a Powerful Tool in the Construction of Biologically Active Nitrogen-Containing Heterocycles

  2016cites this paper
• Cardiomyopathy Dilated Cardiomyopathy in Dialysis Patients — Beneficial Effects of Carvedilol : A Double-Blind , Placebo-Controlled Trial

  2016cites this paper
• Insuffisance cardiaque du nouveau-né et du nourrisson

  2015cites this paper
• Integrating acupuncture into the cardiology clinic: can it play a role?

  2015cites this paper
• Beneficial effects of beta‐blockers on left ventricular function and cellular energy reserve in patients with heart failure

  2013cites this paper
• PDE4 in the human heart – major player or little helper?

  2013cites this paper
• Pharmacological Characterization of Pp-17, a α/β-adrenoceptor Blocking Agent with Antihypertensive Effect

  2013cites this paper
• Describing the Profile of Patients on Concurrent Rifampin and Warfarin Therapy in Western Kenya: A Case Series

  2013cites this paper
• Role of antiischemic agents in the management of non-ST elevation acute coronary syndrome (NSTE-ACS).

  2012cites this paper
• The development of β-adrenergic receptor antagonists for the treatment of heart failure: a paradigm for translational science.

  2011cites this paper
• Chapter 46 – Antagonism of the Sympathetic Nervous System in Heart Failure

  2011cites this paper
• Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology.

  2011cites this paper
• Effect of Acute b-blocker Withholding on Ventilatory Efficiency in Patients With Advanced Chronic Heart Failure

  2010cites this paper
• Effect of acute β-blocker withholding on ventilatory efficiency in patients with advanced chronic heart failure.

  2010cites this paper
• Attivazione adrenergica nello scompenso cardiaco: blocco o riequilibrio?

  2010cites this paper
• The effects of left ventricular assist devices on myocardial function and cardiac nervous system

  2010cites this paper
• The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the beta-blocker metoprolol in severe dilated cardiomyopathy--a prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment.

  2009cites this paper
• The Role of Beta Blockers in Treating Hypertensive Patients

  2009cites this paper
• Heart Failure: Back to Basics for Pharmacists:

  2008cites this paper
• Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans

  2008cites this paper
• Heart Failure: Back to Basics for Pharmacists

  2008cites this paper
• Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure.

  2008cites this paper
• Letter to the Editor Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure

  2008cites this paper
• Adherence to medication in patients with heart failure : effect on mortality and hospitalization

  2008cites this paper
• Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide.

  2007cites this paper
• Tratamiento de la insuficiencia cardíaca con bloqueantes betaadrenérgicos

  2007cites this paper
• A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle.

  2007cites this paper
• Zur Funktion des β3-Adrenozeptors am Herzen: Signaltransduktion, inotroper Effekt und therapeutischer Ausblick

  2006cites this paper
• Beta3-adrenergic stimulation in the human heart: signal transduction, functional implications and therapeutic perspectives.

  2006cites this paper
• Chapter 7 – Pharmacology of Cardiovascular Drugs

  2006cites this paper
• Insuffisance cardiaque du nourrisson et du nouveau-né

  2006cites this paper
• Heart Failure and Resuscitation

  2006cites this paper
• Protection des organes cibles dans l'hypertension à l'aide d'un antagoniste des récepteurs AT1 (losartan) versus un beta-bloqueur (atenolol)

  2006cites this paper
• Retrospective Evaluation for Efficacy and Tolerance of beta-blocker in Heart FailurePatients with Concomitant Diabetes

  2006cites this paper
• Survival in dogs with dilated cardiomyopathy and congestive heart failure treated with digoxin, furosemide and propranolol: A retrospective study of 62 dogs.

  2006cites this paper
• Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.

  2006cites this paper
• [On the function of beta3-adrenoceptors in the human heart: signal transduction, inotropic effect and therapeutic prospects].

  2006cites this paper
• Impact of β-Blocker Dosage Changes during Heart Failure Exacerbation

  2006cites this paper
• Documento de Consenso de Expertos sobre bloqueadores de los receptores β-adrenérgicos

  2005cites this paper
• [Expert Consensus document on beta-adrenergic receptor blockers].

  2005cites this paper
• Dose-Response of Chronic / 3-Blocker Treatment in Heart Failure From Either Idiopathic Dilated or Ischemic Cardiomyopathy

  2005cites this paper
• Synthesis and in vitro pharmacological activity of oxypropanol analogs of labetalol.

  2005cites this paper
• Anti-Hypertension Effect of Vanylidilol: A Phenylaldehyde α/β-Adrenoceptor Blocker with Endothelium-Dependent and K+ Channels Opening-Associated Vasorelaxant Activities

  2004cites this paper
• Expert consensus document on b-adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology Task Force Members , Jos

  2004cites this paper
• Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study

  2004cites this paper
• Expert consensus document on beta-adrenergic receptor blockers.

  2004cites this paper
• Beta-blockade in the management of systolic dysfunction.

  2004influential citation
• New concepts for why beta-blockers are helpful in heart failure

  2004cites this paper
• The use of beta-blockers in the treatment of chronic heart failure.

  2003cites this paper
• Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?

  2003cites this paper
• Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy.

  2003cites this paper
• Pharmacokinetic Considerations of Formulation: Extended-Release Metoprolol Succinate in the Treatment of Heart Failure

  2003cites this paper
• Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection.

  2003cites this paper
• Insuffisance cardiaque du nourrisson et du nouveau-né

  2002cites this paper
• Using carvedilol to treat heart failure.

  2002influential citation
• Vanillylamide-Based Propanolamine Derivative Displays / -Adrenoceptor Blocking and Vasodilating Properties

  2002cites this paper
• Bloqueadores betaadrenérgicos: análisis comparativo

  2002cites this paper
• Beta-adrenergic blockade 2002: a pharmacologic odyssey in chronic heart failure.

  2002cites this paper
• A new aspect of view in synthesizing new type beta-adrenoceptor blockers with ancillary antioxidant activities.

  2001cites this paper
• , ARK 1 Upregulation Induced by Chronic Salt Deprivation in Rats β Cardiac

  2001cites this paper
• Cardiac &bgr;ARK1 Upregulation Induced by Chronic Salt Deprivation in Rats

  2001cites this paper
• Beta-blockers and heart failure

  2001cites this paper
• Pharmacologic Agents in Preventive Cardiology

  2001cites this paper
• Effects Of Digoxin, Furosemide, Enalaprilat And Metoprolol On Endothelial Function In Young Normotensive Subjects

  2001cites this paper
• Bucindolol, a Nonselective &bgr;1‐ and &bgr;2‐Adrenergic Receptor Antagonist, Decreases &bgr;‐Adrenergic Receptor Density in Cultured Embryonic Chick Cardiac Myocyte Membranes

  2001cites this paper
• Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial.

  2001cites this paper
• Dose optimization in drug development: role of phase IV trials

  2001cites this paper
• Management of heart failure in children.

  2000cites this paper
• What Type of β-Blocker Should Be Used to Treat Chronic Heart Failure?

  2000cites this paper
• Vasodilators in the treatment of pediatric heart failure.

  2000cites this paper
• Are all beta blockers the same for heart failure?

  2000cites this paper
• THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE

  2000cites this paper
• What type of beta-blocker should be used to treat chronic heart failure?

  2000cites this paper
• The Control of Adrenergic Function in Heart Failure: Therapeutic Intervention

  2000cites this paper
• beta-blocker therapy: a standard of care for heart failure.

  2000cites this paper
• Beta-adrenergic blocking agents in heart failure.

  2000cites this paper
• Are All ß Blockers the Same for Heart Failure

  2000cites this paper
• Metoprolol

  2000cites this paper
• Pharmacological effects of an aldehyde type alpha/beta-adrenoceptor blocking agent with vasodilating properties.

  2000cites this paper
• Effect of beta-blocker therapy on severe ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy.

  2000cites this paper
• Pharmacological effects of an aldehyde type α/β-adrenoceptor blocking agent with vasodilating properties

  2000cites this paper
• Bridge to ß Blockade in Severe Heart Failure: The Use of Phosphodiesterase Inhibitors

  2000cites this paper
• Metoprolol: a review of its use in chronic heart failure.

  2000cites this paper
• Usefulness of β Blocker Therapy in Patients with Takayasu Arteritis and Moderate or Severe Aortic Regurgitation

  2000cites this paper
• Isoeugenodilol: A vasorelaxant α/β‐adrenoceptor blocker with antioxidant activity

  2000cites this paper
• β‐Blocker Therapy: A Standard of Care for Heart Failure

  2000cites this paper
• Familial Dilated Cardiomyopathy

  2000cites this paper
• Difficult cases in heart failure: Bridge to beta blockade in severe heart failure: the use of phosphodiesterase inhibitors.

  2000cites this paper
• Usefulness of beta blocker therapy in patients with Takayasu arteritis and moderate or severe aortic regurgitation.

  2000cites this paper
• Myocardial G protein-coupled receptor kinases: implications for heart failure therapy.

  1999cites this paper